Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 420

1.

Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.

Tejada Neyra MA, Neuberger U, Reinhardt A, Brugnara G, Bonekamp D, Sill M, Wick A, Jones DTW, Radbruch A, Unterberg A, Debus J, Heiland S, Schlemmer HP, Herold-Mende C, Pfister S, von Deimling A, Wick W, Capper D, Bendszus M, Kickingereder P.

Neuro Oncol. 2018 Aug 9. doi: 10.1093/neuonc/noy134. [Epub ahead of print]

PMID:
30107597
2.

Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.

Friedrich M, Bunse L, Wick W, Platten M.

Curr Opin Oncol. 2018 Aug 9. doi: 10.1097/CCO.0000000000000478. [Epub ahead of print]

PMID:
30102604
3.

Treatment of glioblastoma in adults.

Wick W, Osswald M, Wick A, Winkler F.

Ther Adv Neurol Disord. 2018 Jul 25;11:1756286418790452. doi: 10.1177/1756286418790452. eCollection 2018. Review.

4.

Identification of tumor antigens among the HLA peptidomes of Glioblastoma tumors and plasma.

Shraibman B, Barnea E, Melamed Kadosh D, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, Von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2018 Aug 2. pii: mcp.RA118.000792. doi: 10.1074/mcp.RA118.000792. [Epub ahead of print]

5.

Understanding and Treating Glioblastoma.

Wick W, Platten M.

Neurol Clin. 2018 Aug;36(3):485-499. doi: 10.1016/j.ncl.2018.04.006. Review.

PMID:
30072067
6.

Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients.

Berberich A, Hielscher T, Kickingereder P, Winkler F, Drüschler K, Riedemann L, Arzt M, Kessler T, Platten M, von Deimling A, Wick W, Sahm F, Bendszus M, Wick A.

Int J Radiat Oncol Biol Phys. 2018 Jul 30. pii: S0360-3016(18)33461-8. doi: 10.1016/j.ijrobp.2018.07.2004. [Epub ahead of print]

PMID:
30071292
7.

Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI.

Karimian-Jazi K, Wildemann B, Diem R, Schwarz D, Hielscher T, Wick W, Bendszus M, Breckwoldt MO.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 16;5(5):e480. doi: 10.1212/NXI.0000000000000480. eCollection 2018 Sep.

8.

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

Le Rhun E, Genbrugge E, Stupp R, Chinot OL, Nabors LB, Cloughesy T, Reardon DA, Wick W, Gorlia T, Weller M.

Eur J Cancer. 2018 Jul 20;101:95-104. doi: 10.1016/j.ejca.2018.06.029. [Epub ahead of print]

PMID:
30036741
9.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M.

Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9.

PMID:
29988124
10.

Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients.

Regnery S, Adeberg S, Dreher C, Oberhollenzer J, Meissner JE, Goerke S, Windschuh J, Deike-Hofmann K, Bickelhaupt S, Zaiss M, Radbruch A, Bendszus M, Wick W, Unterberg A, Rieken S, Debus J, Bachert P, Ladd M, Schlemmer HP, Paech D.

Oncotarget. 2018 Jun 19;9(47):28772-28783. doi: 10.18632/oncotarget.25594. eCollection 2018 Jun 19.

11.

Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience.

Capper D, Stichel D, Sahm F, Jones DTW, Schrimpf D, Sill M, Schmid S, Hovestadt V, Reuss DE, Koelsche C, Reinhardt A, Wefers AK, Huang K, Sievers P, Ebrahimi A, Schöler A, Teichmann D, Koch A, Hänggi D, Unterberg A, Platten M, Wick W, Witt O, Milde T, Korshunov A, Pfister SM, von Deimling A.

Acta Neuropathol. 2018 Aug;136(2):181-210. doi: 10.1007/s00401-018-1879-y. Epub 2018 Jul 2.

12.

New glioblastoma heterogeneity atlas - a shared resource.

Wick W, Kessler T.

Nat Rev Neurol. 2018 Aug;14(8):453-454. doi: 10.1038/s41582-018-0038-3. No abstract available.

PMID:
29946076
13.

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide and bevacizumab or placebo.

Ellingson BM, Abrey LE, Garcia J, Chinot O, Wick W, Saran F, Nishikawa R, Henriksson R, Mason WP, Harris RJ, Leu K, Woodworth DC, Mehta A, Raymond C, Chakhoyan A, Pope WB, Cloughesy TF.

Neuro Oncol. 2018 Apr 20. doi: 10.1093/neuonc/noy064. [Epub ahead of print]

PMID:
29897562
14.

Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy.

Debus C, Waltenberger M, Floca R, Afshar-Oromieh A, Bougatf N, Adeberg S, Heiland S, Bendszus M, Wick W, Rieken S, Haberkorn U, Debus J, Knoll M, Abdollahi A.

Sci Rep. 2018 May 8;8(1):7201. doi: 10.1038/s41598-018-25350-7.

15.

Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multi-pool CEST MRI at 7.0 Tesla.

Paech D, Windschuh J, Oberhollenzer J, Dreher C, Sahm F, Meissner JE, Goerke S, Schuenke P, Zaiss M, Regnery S, Bickelhaupt S, Bäumer P, Bendszus M, Wick W, Unterberg A, Bachert P, Ladd ME, Schlemmer HP, Radbruch A.

Neuro Oncol. 2018 May 4. doi: 10.1093/neuonc/noy073. [Epub ahead of print]

PMID:
29733378
16.

Association of Blood Pressure With Short- and Long-Term Functional Outcome After Stroke Thrombectomy: Post Hoc Analysis of the SIESTA Trial.

Schönenberger S, Uhlmann L, Ungerer M, Pfaff J, Nagel S, Klose C, Bendszus M, Wick W, Ringleb PA, Kieser M, Möhlenbruch MA, Bösel J.

Stroke. 2018 Jun;49(6):1451-1456. doi: 10.1161/STROKEAHA.117.019709. Epub 2018 May 2.

PMID:
29720440
17.

Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.

Wick W, Winkler F.

Cancer. 2018 Jul 1;124(13):2674-2676. doi: 10.1002/cncr.31371. Epub 2018 Apr 26. No abstract available.

PMID:
29698549
18.

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.

Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, von Deimling A.

Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23.

PMID:
29687258
19.

Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Apr 5. doi: 10.1093/neuonc/noy053. [Epub ahead of print]

PMID:
29660006
20.

Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.

Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching HG, Baumgarten P, Herold-Mende C, Wick W, Harter PN, Weller M, von Deimling A, Snuderl M, Sen C, Sahm F.

Acta Neuropathol. 2018 Jun;135(6):955-963. doi: 10.1007/s00401-018-1844-9. Epub 2018 Apr 7.

PMID:
29627952
21.

Vaccine Strategies in Gliomas.

Platten M, Bunse L, Riehl D, Bunse T, Ochs K, Wick W.

Curr Treat Options Neurol. 2018 Mar 28;20(5):11. doi: 10.1007/s11940-018-0498-1. Review.

PMID:
29594595
22.

Harmful networks in the brain and beyond.

Winkler F, Wick W.

Science. 2018 Mar 9;359(6380):1100-1101. doi: 10.1126/science.aar5555. No abstract available.

PMID:
29590028
23.

A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.

Wirthschaft P, Bode J, Simon AEM, Hoffmann E, van Laack R, Krüwel T, Dietrich F, Bucher D, Hahn A, Sahm F, Breckwoldt MO, Kurz FT, Hielscher T, Fischer B, Dross N, Ruiz de Almodovar C, von Deimling A, Herold-Mende C, Plass C, Boulant S, Wiestler B, Reifenberger G, Lichter P, Wick W, Tews B.

Int J Cancer. 2018 Mar 26. doi: 10.1002/ijc.31404. [Epub ahead of print]

PMID:
29582423
24.

Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.

Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE, Koelsche C, Huang K, Wefers AK, Hovestadt V, Sill M, Gramatzki D, Felsberg J, Reifenberger G, Koch A, Thomale UW, Becker A, Hans VH, Prinz M, Staszewski O, Acker T, Dohmen H, Hartmann C, Mueller W, Tuffaha MSA, Paulus W, Heß K, Brokinkel B, Schittenhelm J, Monoranu CM, Kessler AF, Loehr M, Buslei R, Deckert M, Mawrin C, Kohlhof P, Hewer E, Olar A, Rodriguez FJ, Giannini C, NageswaraRao AA, Tabori U, Nunes NM, Weller M, Pohl U, Jaunmuktane Z, Brandner S, Unterberg A, Hänggi D, Platten M, Pfister SM, Wick W, Herold-Mende C, Jones DTW, von Deimling A, Capper D.

Acta Neuropathol. 2018 Aug;136(2):273-291. doi: 10.1007/s00401-018-1837-8. Epub 2018 Mar 21.

PMID:
29564591
25.

Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.

Winkler F, Osswald M, Wick W.

Oncol Res Treat. 2018;41(4):181-186. doi: 10.1159/000488258. Epub 2018 Mar 23.

PMID:
29562225
26.

What's New in Grade II and Grade III Gliomas?

Miller JJ, Wick W.

Semin Neurol. 2018 Feb;38(1):41-49. doi: 10.1055/s-0037-1620275. Epub 2018 Mar 16.

PMID:
29548051
27.

Neuro-Oncology.

Batchelor T, Wick W.

Semin Neurol. 2018 Feb;38(1):3-4. doi: 10.1055/s-0038-1635105. Epub 2018 Mar 16. No abstract available.

PMID:
29548045
28.

DNA methylation-based classification of central nervous system tumours.

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM.

Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.

PMID:
29539639
29.

Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry.

Longuespée R, Wefers AK, De Vita E, Miller AK, Reuss DE, Wick W, Herold-Mende C, Kriegsmann M, Schirmacher P, von Deimling A, Pusch S.

Acta Neuropathol Commun. 2018 Mar 2;6(1):21. doi: 10.1186/s40478-018-0523-3.

30.

cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.

Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W, Wesseling P.

Acta Neuropathol. 2018 Apr;135(4):639-642. doi: 10.1007/s00401-018-1826-y. Epub 2018 Mar 1. No abstract available.

PMID:
29497819
31.

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.

Blaes J, Thomé CM, Pfenning PN, Rübmann P, Sahm F, Wick A, Bunse T, Schmenger T, Sykora J, von Deimling A, Wiestler B, Merz C, Jugold M, Haberkorn U, Abdollahi A, Debus J, Gieffers C, Kunz C, Bendszus M, Kluge M, Platten M, Fricke H, Wick W, Lemke D.

Mol Cancer Res. 2018 May;16(5):767-776. doi: 10.1158/1541-7786.MCR-17-0563. Epub 2018 Feb 16.

PMID:
29453321
32.

cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC).

Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W, van den Bent M.

Acta Neuropathol. 2018 Mar;135(3):481-484. doi: 10.1007/s00401-018-1808-0. Epub 2018 Jan 25. No abstract available.

PMID:
29372318
33.

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.

Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME.

Acta Neuropathol. 2018 Apr;135(4):601-615. doi: 10.1007/s00401-018-1810-6. Epub 2018 Jan 24.

34.

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH.

Lancet Oncol. 2017 Dec;18(12):e709-e710. doi: 10.1016/S1470-2045(17)30856-2. No abstract available.

PMID:
29208433
35.

Increased Delay Between Gadolinium Chelate Administration and T1-Weighted Magnetic Resonance Imaging Acquisition Increases Contrast-Enhancing Tumor Volumes and T1 Intensities in Brain Tumor Patients.

Piechotta PL, Bonekamp D, Sill M, Wick A, Wick W, Bendszus M, Kickingereder P.

Invest Radiol. 2018 Apr;53(4):223-228. doi: 10.1097/RLI.0000000000000432.

PMID:
29200014
36.

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.

Pfaff E, Kessler T, Balasubramanian GP, Berberich A, Schrimpf D, Wick A, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Capper D, Schenkel I, Eisenmenger A, Dettmer S, Brors B, Platten M, Pfister SM, von Deimling A, Jones DTW, Wick W, Sahm F.

Neuro Oncol. 2018 May 18;20(6):826-837. doi: 10.1093/neuonc/nox216.

PMID:
29165638
37.

Lomustine and Bevacizumab in Progressive Glioblastoma.

Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ.

N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358.

38.

Drug Repositioning Meets Precision in Glioblastoma.

Wick W, Kessler T.

Clin Cancer Res. 2018 Jan 15;24(2):256-258. doi: 10.1158/1078-0432.CCR-17-2989. Epub 2017 Nov 13.

PMID:
29133572
39.

Sequential proton boost after standard chemoradiation for high-grade glioma.

Adeberg S, Bernhardt D, Harrabi SB, Uhl M, Paul A, Bougatf N, Verma V, Unterberg A, Wick W, Haberer T, Combs SE, Herfarth K, Debus J, Rieken S.

Radiother Oncol. 2017 Nov;125(2):266-272. doi: 10.1016/j.radonc.2017.09.040. Epub 2017 Oct 16.

PMID:
29050959
40.

Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma.

Kickingereder P, Neuberger U, Bonekamp D, Piechotta PL, Götz M, Wick A, Sill M, Kratz A, Shinohara RT, Jones DTW, Radbruch A, Muschelli J, Unterberg A, Debus J, Schlemmer HP, Herold-Mende C, Pfister S, von Deimling A, Wick W, Capper D, Maier-Hein KH, Bendszus M.

Neuro Oncol. 2018 May 18;20(6):848-857. doi: 10.1093/neuonc/nox188.

PMID:
29036412
41.

Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography.

Jende JME, Hauck GH, Diem R, Weiler M, Heiland S, Wildemann B, Korporal-Kuhnke M, Wick W, Hayes JM, Pfaff J, Pham M, Bendszus M, Kollmer J.

Ann Neurol. 2017 Nov;82(5):676-685. doi: 10.1002/ana.25068. Epub 2017 Oct 26.

PMID:
29023976
42.

Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.

Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, Nishikawa R, Mason WP, Henriksson R, Saran F, Kickingereder P, Platten M, Sandmann T, Abrey LE, Cloughesy TF, Bendszus M, Wick W.

Neuro Oncol. 2018 Mar 27;20(4):557-566. doi: 10.1093/neuonc/nox162.

PMID:
29016943
43.

Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).

Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs SE, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P.

Neuro Oncol. 2018 Feb 19;20(3):400-410. doi: 10.1093/neuonc/nox155.

PMID:
29016837
44.

Glioblastoma in elderly patients: solid conclusions built on shifting sand?

Wick A, Kessler T, Elia AEH, Winkler F, Batchelor TT, Platten M, Wick W.

Neuro Oncol. 2018 Jan 22;20(2):174-183. doi: 10.1093/neuonc/nox133.

PMID:
29016815
45.

Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.

Kessler T, Sahm F, Sadik A, Stichel D, Hertenstein A, Reifenberger G, Zacher A, Sabel M, Tabatabai G, Steinbach J, Sure U, Krex D, Grosu AL, Bewerunge-Hudler M, Jones D, Pfister SM, Weller M, Opitz C, Bendszus M, von Deimling A, Platten M, Wick W.

Neuro Oncol. 2018 Feb 19;20(3):367-379. doi: 10.1093/neuonc/nox160.

PMID:
29016808
46.

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rudà R, Preusser M; EANO Executive Board and ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99. doi: 10.1093/annonc/mdx221. No abstract available.

PMID:
28881917
47.

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators.

Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23.

48.

K27M-mutant histone-3 as a novel target for glioma immunotherapy.

Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, Platten M.

Oncoimmunology. 2017 May 12;6(7):e1328340. doi: 10.1080/2162402X.2017.1328340. eCollection 2017.

49.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8.

50.

Evidence-based management of adult patients with diffuse glioma - Authors' reply.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Aug;18(8):e430-e431. doi: 10.1016/S1470-2045(17)30515-6. Epub 2017 Jul 26. No abstract available.

PMID:
28759377

Supplemental Content

Support Center